Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
67.69-0.76 (-1.11%)
As of 11:12 AM EDT. Market open.
People also watch:
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open68.06
Prev Close68.45
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range67.39 - 68.17
52wk Range24.83 - 93.82
1y Target EstN/A
Market Cap86.09B
P/E Ratio (ttm)21.05
BetaN/A
Volume1,596,978
Avg Vol (3m)9,830
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • GlobeNewswire26 minutes ago

    Sanofi : BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika

    BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika - Funds will be used for phase II development and manufacturing - Paris, France - September 26, 2016 - Sanofi and its vaccines global business ...

  • The Internet of Medical Things: 6 Stocks in Focus
    Zacks2 hours ago

    The Internet of Medical Things: 6 Stocks in Focus

    Intelligent care is where modern medicine seems to be headed with pharma and tech companies collaborating for better healthcare solutions.

  • American City Business Journals4 hours ago

    ​FDA set to decide on two likely blockbuster drugs by Sanofi Genzyme

    The second of two potential drugs for immune system disorders that are together expected to bring in peak annual revenues of between $3 billion and $7 billion to Sanofi Genzyme and a New York based partner in the next few years is expected to have a decision on U.S. approval by next spring. Both drugs are partnered between the Cambridge-based division of Sanofi (SNY) that’s focused on specialty pharmaceuticals (formerly called simply Genzyme), and Tarrytown, N.Y.-based Regeneron Pharmaceuticals (REGN). Both are also biologics (protein-based) and while they weren’t developed in Cambridge, they will be marketed by Sanofi Genzyme under a reorganization of the parent company announced more than a year ago.